Brokers Set Expectations for Zevra Therapeutics, Inc.’s FY2024 Earnings (NASDAQ:ZVRA)

Zevra Therapeutics, Inc. (NASDAQ:ZVRA) – Equities researchers at Roth Capital dropped their FY2024 earnings estimates for Zevra Therapeutics in a note issued to investors on Tuesday, September 24th. Roth Capital analyst J. Aschoff now anticipates that the company will post earnings per share of ($1.57) for the year, down from their prior estimate of ($1.49). The consensus estimate for Zevra Therapeutics’ current full-year earnings is ($1.59) per share. Roth Capital also issued estimates for Zevra Therapeutics’ Q4 2024 earnings at ($0.32) EPS, FY2025 earnings at $0.09 EPS, FY2026 earnings at $1.20 EPS, FY2027 earnings at $2.36 EPS and FY2028 earnings at $2.28 EPS.

Zevra Therapeutics (NASDAQ:ZVRA) last released its quarterly earnings results on Tuesday, August 13th. The company reported ($0.48) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.47) by ($0.01). The firm had revenue of $4.45 million for the quarter, compared to analysts’ expectations of $4.08 million. Zevra Therapeutics had a negative return on equity of 124.85% and a negative net margin of 274.10%. During the same quarter in the prior year, the business earned ($0.15) EPS.

A number of other research firms have also issued reports on ZVRA. Maxim Group raised their price target on Zevra Therapeutics from $18.00 to $25.00 and gave the stock a “buy” rating in a report on Tuesday. William Blair upgraded Zevra Therapeutics to a “strong-buy” rating in a research note on Friday, August 30th. Canaccord Genuity Group cut their price target on Zevra Therapeutics from $24.00 to $22.00 and set a “buy” rating for the company in a research note on Wednesday, September 18th. Roth Mkm increased their price target on Zevra Therapeutics from $19.00 to $21.00 and gave the stock a “buy” rating in a report on Tuesday. Finally, HC Wainwright boosted their price objective on shares of Zevra Therapeutics from $18.00 to $20.00 and gave the company a “buy” rating in a research note on Friday, September 20th. Six research analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, Zevra Therapeutics has an average rating of “Buy” and a consensus price target of $21.00.

Zevra Therapeutics Stock Down 5.3 %

ZVRA stock opened at $6.92 on Thursday. The company has a fifty day moving average price of $7.16 and a 200 day moving average price of $5.76. Zevra Therapeutics has a 12 month low of $3.89 and a 12 month high of $8.95. The company has a debt-to-equity ratio of 1.80, a current ratio of 2.00 and a quick ratio of 2.00. The company has a market cap of $364.13 million, a price-to-earnings ratio of -5.13 and a beta of 1.94.

Insider Activity at Zevra Therapeutics

In related news, Director Thomas Anderson bought 10,000 shares of the stock in a transaction on Tuesday, July 16th. The shares were bought at an average cost of $6.81 per share, for a total transaction of $68,100.00. Following the completion of the transaction, the director now owns 20,000 shares of the company’s stock, valued at approximately $136,200. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Insiders purchased 22,000 shares of company stock worth $140,340 over the last 90 days. Company insiders own 2.40% of the company’s stock.

Institutional Trading of Zevra Therapeutics

A number of institutional investors have recently bought and sold shares of the company. Price T Rowe Associates Inc. MD purchased a new position in shares of Zevra Therapeutics in the first quarter valued at $64,000. The Manufacturers Life Insurance Company increased its holdings in Zevra Therapeutics by 15.2% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 18,573 shares of the company’s stock valued at $91,000 after acquiring an additional 2,452 shares in the last quarter. Focus Financial Network Inc. ADV acquired a new position in Zevra Therapeutics during the fourth quarter worth about $141,000. Virtu Financial LLC purchased a new stake in shares of Zevra Therapeutics in the fourth quarter valued at about $177,000. Finally, Jacobs Levy Equity Management Inc. grew its position in shares of Zevra Therapeutics by 102.4% in the first quarter. Jacobs Levy Equity Management Inc. now owns 34,707 shares of the company’s stock valued at $201,000 after purchasing an additional 17,557 shares during the last quarter. 35.03% of the stock is currently owned by hedge funds and other institutional investors.

About Zevra Therapeutics

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.